Cannabis as a Complementary Treatment in Multiple Sclerosis

Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) afflicting over 77,000 Canadians. Unfortunately, the therapeutic arsenal to relieve MS symptoms is limited. It is therefore essential to develop better approaches to treat the symptoms of MS. The use of cannabis for recreational purposes is now legal in Canada. However, for many years, people with Multiple Sclerosis (PwMS) have used cannabis either to relax, to reduce pain and spasticity, or to improve sleep and daily functioning. Currently, there is little scientifically established evidence that cannabis works on these symptoms in people with MS. It is therefore important to carry out studies to better understand the efficacy Δ-9-tetrahydrocannabinol (THC), and cannabidiol (CBD) on MS symptoms . THC is known for its analgesic, neuroprotective and anti-inflammatory properties and CBD seems to have positive effects on anxiety and cognitive abilities (memory, concentration). For this study, investigators hypothesize that administering different doses of THC alone, CBD alone, and THC and CBD combined will result in a significant beneficial effect on spasticity relief compared to placebo.

NCT Number	NCT05092191
Lead Sponsor	Centre hospitalier de l'Université de Montréal (CHUM) Collaborators: Canadian Institutes of Health Research (CIHR), Multiple Sclerosis Society of Canada
Conditions	Multiple Sclerosis
Enrollment	250 participants
Start Date	2022-11-10
Primary Completion	2025-04-10 (estimated)
Study Completion	2025-05-10 (estimated)
Updated on ClinicalTrials.gov	2024-12-13